Tsumura Expands in China with Strategic Acquisition

Tsumura & Co ( (JP:4540) ) has issued an announcement.

Tsumura & Co. has announced that its subsidiary, Tsumura China Inc., will acquire a 51% stake in Shanghai Hongqiao Traditional Chinese Drug Pieces Co., Ltd. This strategic acquisition aims to expand Tsumura’s crude drug platform in China, leveraging Hongqiao’s sales capabilities and Tsumura’s expertise in personalized medicine and quality assurance. The move is expected to enhance product quality and increase convenience for patients, aligning with Tsumura’s vision to contribute to the health of the Chinese population.

The most recent analyst rating on (JP:4540) stock is a Buy with a Yen6000.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.

More about Tsumura & Co

Tsumura & Co. is a company operating in the pharmaceutical industry, focusing on Kampo and traditional Chinese medicines. The company aims to contribute to well-being by providing evidence-based medicinal products and services tailored to individual needs. Tsumura operates through various platforms, including the formulation, crude drug, and research platforms, to enhance the quality and availability of traditional medicinal products.

Average Trading Volume: 536,421

Technical Sentiment Signal: Sell

Current Market Cap: Yen258.3B

See more data about 4540 stock on TipRanks’ Stock Analysis page.